A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland

dc.contributor.authorSipponen Taina
dc.contributor.authoraf Björkesten Clas-Göran
dc.contributor.authorHallinen Taru
dc.contributor.authorIlus Tuire
dc.contributor.authorSoini Erkki
dc.contributor.authorEberl Anja
dc.contributor.authorHeikura Mikko
dc.contributor.authorKellokumpu Mikko
dc.contributor.authorKoskela Ritva
dc.contributor.authorNielsen Christian
dc.contributor.authorNuutinen Heikki
dc.contributor.authorHeikkinen Markku
dc.contributor.authorSuhonen Ulla-Maija
dc.contributor.authorTillonen Jyrki
dc.contributor.authorWennerström E. Christina M.
dc.contributor.authorBorsi Andras
dc.contributor.authorKoivunen Minni R.
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.converis.publication-id57635297
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/57635297
dc.date.accessioned2022-10-28T14:21:22Z
dc.date.available2022-10-28T14:21:22Z
dc.description.abstract<b>Background</b> Real-world evidence to support optimal ustekinumab dosing for refractory Crohn's disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explore ustekinumab dosing dynamics and optimization, identify possible clinical predictors of dose intensification, and to evaluate ustekinumab trough concentrations (TCs) and concomitant medication use in Finland.<div><b>Methods</b> Information gathered from17 Finnish hospitals included clinical chart data from 155 adult CD patients who received intravenous ustekinumab induction during 2017-2018. Data on ustekinumab dosing and TCs, concomitant corticosteroid and immunosuppressant use, and antiustekinumab antibodies were analyzed in a two-year follow-up, subject to availability.</div><div><b>Results </b> Among 140 patients onustekinumab maintenance therapy, dose optimization was required in 55(39%) of the patients, and 41/47 dose-intensified patients (87%) persisted on ustekinumab. At baseline, dose-intensified patient group had significantly higher C-reactive protein (CRP) levels, and at week 16, significantly lower ustekinumab TCs than in patients without dose intensification. Irrespective of dose optimization, a statistically significant reduction in the use of corticosteroids was observed at both 16 weeks and one year, coupled with an increased proportion of patients on ustekinumab monotherapy. Antiustekinumab antibodies were undetectable in all 28 samples from 25 patients collected throughout the study period.</div><div><b>Conclusions</b> Nearly a third of all CD patients on ustekinumab maintenance therapy, with a history of treatment-refractory and long-standing disease, required dose intensification. These patients persisted on ustekinumab and had significant reduction of corticosteroid use. Increased baseline CRP was identified as the sole indicator of dose intensification.</div>
dc.format.pagerange661
dc.format.pagerange770
dc.identifier.eissn1502-7708
dc.identifier.jour-issn0036-5521
dc.identifier.olddbid187777
dc.identifier.oldhandle10024/170871
dc.identifier.urihttps://www.utupub.fi/handle/11111/43264
dc.identifier.urlhttps://www.tandfonline.com/doi/full/10.1080/00365521.2021.1906315
dc.identifier.urnURN:NBN:fi-fe2021093049036
dc.language.isoen
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherTAYLOR & FRANCIS LTD
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1080/00365521.2021.1906315
dc.relation.ispartofjournalScandinavian Journal of Gastroenterology
dc.relation.issue6
dc.relation.volume56
dc.source.identifierhttps://www.utupub.fi/handle/10024/170871
dc.titleA nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
NuutinenEtAl2021ANationwideRealWorldStudy.pdf
Size:
1.95 MB
Format:
Adobe Portable Document Format
Description:
Publisher's pdf